Onkologische Schwerpunktpraxis Bielefeld

Industry / private company


Location: Bielefeld, Germany (DE) DE

ISNI: 000000405581094

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial (2023) Link T, Blohmer JU, Schmitt WD, Kuhlmann JD, Just M, Untch M, Stoetzer OJ, et al. Journal article Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC) (2022) Reinisch M, Blohmer JU, Link T, Just M, Untch M, Stoetzer O, Fasching P, et al. Conference contribution Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients with Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial (2022) Blohmer JU, Link T, Reinisch M, Just M, Untch M, Stotzer O, Fasching P, et al. Journal article Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials (2021) Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, Wimberger P, et al. Journal article GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status (2020) Link T, Blohmer JU, Just M, Untch M, Stoetzer O, Fasching P, Schneeweiss A, et al. Conference contribution Nab-paclitaxel improves disease-free survival in early breast cancer: GBG 69–Geparsepto (2019) Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al. Journal article Pet positivity after 2 cycles of abvd is a risk factor in patients with early-stage favorable Hodgkin lymphoma treated in the phase 3 GHSG HD16 study (2019) Fuchs M, Goergen H, Kobe C, Kuhnert G, Hitz F, Greil R, Sasse S, et al. Conference contribution Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial (2019) Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, zu Eulenburg C, et al. Journal article Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants (2017) Hehlmann R, Lauseker M, Saussele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, et al. Journal article